Solid Biosciences (SLDB) Return on Equity (2018 - 2024)
Historic Return on Equity for Solid Biosciences (SLDB) over the last 7 years, with Q3 2024 value amounting to 0.57%.
- Solid Biosciences' Return on Equity rose 1400.0% to 0.57% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.57%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.57% for FY2023, which is 800.0% down from last year.
- Per Solid Biosciences' latest filing, its Return on Equity stood at 0.57% for Q3 2024, which was up 1400.0% from 0.45% recorded in Q2 2024.
- Over the past 5 years, Solid Biosciences' Return on Equity peaked at 0.09% during Q3 2021, and registered a low of 3.14% during Q3 2020.
- In the last 5 years, Solid Biosciences' Return on Equity had a median value of 0.55% in 2023 and averaged 0.81%.
- Per our database at Business Quant, Solid Biosciences' Return on Equity tumbled by -19800bps in 2020 and then surged by 30500bps in 2021.
- Solid Biosciences' Return on Equity (Quarter) stood at 1.14% in 2020, then soared by 92bps to 0.09% in 2021, then tumbled by -378bps to 0.44% in 2022, then tumbled by -62bps to 0.72% in 2023, then increased by 20bps to 0.57% in 2024.
- Its Return on Equity stands at 0.57% for Q3 2024, versus 0.45% for Q2 2024 and 0.54% for Q1 2024.